Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Jinsai Pharmaceutical received clinical trial approval from China's drug regulator for GenSci133 as an osteoporosis treatment, according to a Saturday filing with the Shenzhen bourse.
The drug is indicated for subcutaneous injection every three to six months, the filing said.
Shares in the drug company fell 1% during afternoon trading on Monday.